NBIX News and Press, Neurocrine Biosciences Inc.

2024-07-01 11:55:27 ET More on Neurocrine Biosciences Neurocrine Biosciences, Inc. (NBIX) Q1 2024 Earnings Call Transcript Neurocrine: Success Continues To Roll In With Positive MDD Treatment Data Neurocrine Biosciences CEO Gorman stepping down in October Neu...

Neurocrine Biosciences Announces U.S. FDA Accepts New Drug Applications and Grants Priority Review for Crinecerfont for Pediatric and Adult Patients with CAH PR Newswire PDUFA Target Action Dates in Late December 2024 Highly Selective CRF 1 Antagonist is the Potent...

2024-06-07 10:57:58 ET Summary Since Richard Francis became CEO in early 2023, his 'Pivot to Growth' strategy has continued to bear fruit. On April 16, the FDA approved Selarsdi, a biosimilar of Stelara, which earned Johnson & Johnson about $2.45 billion in the first quarter o...

2024-06-05 11:52:26 ET Summary Voyager Therapeutics, Inc. is a biotech company focused on developing gene-based therapies for neurological conditions. The company has made progress in its pipeline, including the start of the Phase 1 clinical trial for VY-TAU01, its Alzheimer's dis...

2024-06-04 15:35:31 ET More on iShares Russell Mid-Cap ETF: Small and midcap pair trades for every sector - Oppenheimer Seeking Alpha’s Quant Rating on iShares Russell Mid-Cap ETF Dividend scorecard for iShares Russell Mid-Cap ETF Read the full artic...

Neurocrine Biosciences Presented CAHtalyst™ Phase 3 Pediatric and Adult Studies, CAHtalog™ Registry and Disease- and Glucocorticoid-Related Comorbidities Data in CAH at ENDO 2024 PR Newswire SAN DIEGO , June 3, 2024 /PRNewswire/ -- Neurocrine Bios...

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Pediatric Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire -          CAHtalyst™ Pediatr...

Neurocrine Biosciences Announces Publication of Primary CAHtalyst™ Adult Phase 3 Study Results of Crinecerfont for the Treatment of CAH in The New England Journal of Medicine PR Newswire -          CAHtalyst™ Adult Phase...

Neurocrine Biosciences to Participate at Investor Conferences in June PR Newswire Jefferies Global Healthcare Conference on June 5 in New York Goldman Sachs 45 th Annual Global Healthcare Conference on June 13 in Miami SAN DIEGO , ...

2024-05-28 17:04:47 ET Gainers: Blue World Acquisition  ( BWAQ ) +57% . Insmed  ( INSM ) +33% . Vivid Seats  ( SEAT ) +8% . Ocular Therapeutix ( OCUL ) +7% . Mind Medicine  ( MNMD ) +7% . Losers: Inhib...